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Cardiovascular Risk Factors in Women With
Primary Sjögren’s Syndrome: United Kingdom
Primary Sjögren’s Syndrome Registry Results
M. JUAREZ,1 T. E. TOMS,2 P. DE PABLO,1 S. MITCHELL,3 S. BOWMAN,4 P. NIGHTINGALE,4
E. J. PRICE,5 B. GRIFFITHS,3 J. HUNTER,6 M. GUPTA,6 M. BOMBARDIERI,7 N. SUTCLIFFE,7
C. PITZALIS,7 C. PEASE,8 J. ANDREWS,8 P. EMERY,8 M. REGAN,9 I. GILES,10 D. ISENBERG,10
R. MOOTS,11 K. S. COLLINS,3 W. F. NG,3 AND G. D. KITAS,12 ON BEHALF OF THE UK PRIMARY
SJÖGREN’S SYNDROME REGISTRY
Objective. To determine the prevalence of traditional cardiovascular risk factors using established deﬁnitions in a large
cohort of clinically well-characterized primary Sjo¨gren’s syndrome (SS) patients and to compare them to healthy controls.
Methods. Data on cardiovascular risk factors in primary SS patients and controls were collected prospectively using a
standardized pro forma. Cardiovascular risk factors were deﬁned according to established deﬁnitions. The prevalence of
cardiovascular risk factors in the primary SS group was determined and compared to that in the control group.
Results. Primary SS patients had a higher prevalence of hypertension (28–50% versus 15.5–25.6%; P < 0.01) and hypertri-
glyceridemia (21% versus 9.5%; P 0.002) than age- and sex-matched healthy controls. Furthermore, a signiﬁcant percentage
(56%) of hypertensive patients expected to be on antihypertensive treatment according to best practice was not receiving it.
Conclusion. PrimarySSpatients aremore than2 timesmore likely to experiencehypertensionandhypertriglyceridemia thanage-
and sex-matched healthy controls. Additionally, hypertension is underdiagnosed and suboptimally treated in primary SS.
INTRODUCTION
The association between cardiovascular risk and chronic
multisystem inﬂammatory conditions has been the subject
of a large body of research. There is compelling evidence
of increased cardiovascular mortality and morbidity in
conditions such as rheumatoid arthritis (RA) (1–3) and
systemic lupus erythematosus (SLE) (4). In RA, the excess
cardiovascular risk is attributed to a combination of tradi-
tional and novel cardiovascular risk factors (5) and is a key
contributor to the overall mortality and morbidity of this
condition. Patients with RA have an increased cardiovas-
cular risk that is comparable to that of patients with dia-
betes mellitus (6). These observations have led to the rec-
The copyright line for this article was changed on 23 July
2015 after original online publication.
Supported by a Medical Research Council grant
(G0800629) to Drs. Bowman, Grifﬁths, and Ng, by the British
Sjögren’s Syndrome Association, and by Newcastle University
for the substudy. This study also received infrastructure sup-
port from the Newcastle NIHR Biomedical Research Centre in
Ageing and Chronic Diseases, Northumberland, Tyne and
Wear Comprehensive Local Research Network, and the Com-
prehensive Local Research Networks to the recruiting centers.
1M. Juarez, LMS, P. de Pablo, MD, MPh, PhD: University
of Birmingham, Birmingham, UK; 2T. E. Toms, MBChB,
MRCP, PhD: Dudley Group of Hospitals NHS Trust, Dudley,
UK; 3S. Mitchell, BSc(Hons), B. Grifﬁths, MD, FRCP, K. S.
Collins, MBBS, MRes, W. F. Ng, PhD, FRCP: Newcastle Uni-
versity, Newcastle upon Tyne, UK; 4S. Bowman, PhD, FRCP,
P. Nightingale, PhD: University Hospital Birmingham,
Birmingham, UK; 5E. J. Price, MBChB, FRCP, MD: Great
Western Hospitals NHS Foundation Trust, Swindon, UK;
6J. Hunter, MBChB, M. Gupta, MD: Gartnavel General Hos-
pital, Glasgow, UK; 7M. Bombardieri, MD, PhD, N. Sutcliffe,
MD, FRCP, C. Pitzalis, MD, PhD, FRCP: Barts and the Lon-
don NHS Trust, London, UK; 8C. Pease, MD, FRCP, J.
Andrews, MBChB(Hons), MD, MRCP, P. Emery, MA, MD,
FRCP: University of Leeds & NIHR Leeds Musculoskeletal
Biomedical Research Unit, Leeds Teaching Hospitals Trust,
Leeds, UK; 9M. Regan, MB, FRCP: Derbyshire Royal Inﬁr-
mary NHS Foundation Trust, Derby, UK; 10I. Giles, PhD,
MRCP, D. Isenberg, MD, FRCP: University College London
Hospitals NHS Foundation Trust, London, UK; 11R. Moots,
MD, PhD: Aintree University Hospitals NHS Foundation
Trust, Liverpool, UK; 12G. D. Kitas, MD, PhD, FRCP: Dudley
Group of Hospitals NHS Trust, Dudley, UK, and Manchester
University, Manchester, UK. Members of the UK Primary
Sjögren’s Syndrome Registry are listed in Appendix A.
Arthritis Care & Research
Vol. 66, No. 5, May 2014, pp 757–764
DOI 10.1002/acr.22227
© 2014 The Authors. Arthritis Care & Research is published by Wiley
Periodicals, Inc. on behalf of the American College of Rheumatology.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited.
ORIGINAL ARTICLE
757
ommendation of annual cardiovascular risk assessment for
all RA patients (7).
Primary Sjögren’s syndrome (SS) is an autoimmune dis-
order characterized by chronic multisystem inﬂammation
with shared pathophysiology with SLE and RA. However,
the links between primary SS and cardiovascular disease
(CVD) remain unclear. Five studies have reported on the
prevalence of traditional cardiovascular risk factors in pri-
mary SS patients (8–11), with 3 of them primarily de-
signed for this purpose (8,9,12). The results of these stud-
ies differ. Lodde et al (12) investigated the lipid proﬁle of
46 primary SS patients and found lower high-density li-
poprotein (HDL) and total cholesterol levels than in xer-
ostomic controls (n  12). In contrast, Cruz et al reported
similar lipid proﬁles in primary SS patients (n  73) and
controls (n  65) (8). More recently, Perez de Lis et al
reported that diabetes mellitus and hypertriglyceridemia
are more prevalent in primary SS than in primary care
patients in Spain (9). These studies have used different
methodologies and deﬁnitions for cardiovascular risk fac-
tors and have reached varying conclusions.
In this study, we determined the prevalence of tradi-
tional cardiovascular risk factors using established deﬁni-
tions in a large well-characterized primary SS patient co-
hort in the UK (13).
PATIENTS AND METHODS
Study subjects. Data from 543 patients with primary SS
(5 males, 538 females) recruited to the UK Primary
Sjögren’s Syndrome Registry (UKPSSR) cohort (13) from
30 centers were analyzed. All patients fulﬁlled the Amer-
ican-European Consensus Group (AECG) criteria for the
classiﬁcation of primary SS (14). Data on cardiovascular
risk were prospectively collected as a predetermined sub-
study of the UKPSSR (13).
Data for the healthy control group (n  473; 63 males,
410 females) were derived from 2 cohorts. A parallel con-
trol group was recruited alongside the UKPSSR cohort
using a “ﬁnd a friend approach” (n 111). Brieﬂy, patients
were asked to bring a friend (non–blood relative) to their
research clinic visit and data were collected from these
healthy individuals as well as from the patients. These
controls were age and sex matched to the primary SS
patients. The second control group (n  362) came from a
study undertaken at Great Western Hospital NHS Founda-
tion Trust, UK with the primary aim to analyze the rela-
tionship between C-reactive protein (CRP) and obesity in
healthy individuals.
All studies had Research Ethics Committee approval
and participants gave written consent according to the
Declaration of Helsinki. Data collection was standardized
for patients and controls. As only 5 of the primary SS
patients were male, subsequent analysis was performed on
female participants only.
Deﬁnitions of traditional cardiovascular risk factors.
Traditional cardiovascular risk factors were deﬁned ac-
cording to established criteria. Hypertension was classi-
ﬁed using the following World Health Organization
(WHO) deﬁnitions (15): systolic blood pressure (SBP)
140 mm Hg or diastolic blood pressure (DBP) 90 mm
Hg, and the following National Cholesterol Education Pro-
gramme (NCEP) deﬁnitions (16): SBP 130 mm Hg or
DBP 85 mm Hg or receiving antihypertensive treatment.
Abnormal lipid values were deﬁned according to the
following NCEP guidelines (16): total cholesterol 6.2
mmoles/liter, low-density lipoprotein (LDL) 4.13
mmoles/liter, HDL 1.03 mmoles/liter, and triglycerides
1.7 mmoles/liter. Obesity was deﬁned as a body mass
index (BMI) 30 kg/m2 (15). Smoking was categorized as
current, ex-smoker, and never smoked. Family history of
CVD and the presence of diabetes mellitus were assessed
from medical records and clinical consultation. Blood
pressure was the mean of 3 measurements taken at 5-min-
ute intervals after at least a 5-minute rest. Fasting (8
hours) blood glucose, lipid proﬁle (total cholesterol, trig-
lycerides, HDL, and LDL), and CRP levels were measured
using routine laboratory methods.
Cardiovascular events. Self-reported cardiovascular
events were recorded at recruitment. Events included
myocardial infarction (MI), transient ischemic attacks
and/or strokes (collectively referred to as strokes), and
peripheral vascular disease.
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Signiﬁcance & Innovations
● Cardiovascular risk is not routinely assessed in
primary Sjögren’s syndrome (SS) patients, while it
is in other chronic autoimmune conditions such as
rheumatoid arthritis.
● We set out to determine whether primary SS pa-
tients had a higher prevalence of cardiovascular
risk factors than healthy controls.
● Female primary SS patients are more than 2 times
more likely to experience hypertension and hyper-
triglyceridemia than age-matched healthy con-
trols.
● Hypertension in primary SS is underdiagnosed
and undertreated.
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Autoantibody test. Anti-Ro and anti-La antibodies were
measured in a single laboratory (Newcastle Hospitals
NHS Foundation Trust) using the Euroassay anti-ENA Pro-
ﬁle Plus according to manufacturer’s protocol (Euroim-
mun AG).
Statistical analysis. All analyses were carried out with
PASW 18.0 (SPSS). Values were expressed as percentages,
means, and medians as appropriate. Comparisons were
done using chi-square test and Fisher’s exact test for
categorical data and Mann-Whitney test for nonparametric
continuous data. Logistic regression was used to adjust for
confounders. Subset analysis was carried out in age-
matched primary SS patients and healthy controls. Pa-
tients and healthy controls were matched 1:1 on age,
rounded to the nearest year. A random number was gen-
erated for each individual using Microsoft Excel, and for
each age those individuals in the available pool of possible
exact matches with the lowest random numbers were se-
lected until sufﬁcient matches were obtained.
RESULTS
Data from 538 female primary SS patients fulﬁlling the
AECG criteria for the classiﬁcation of primary SS were
included. Patients’ mean  SD age was 59  12.4 years.
All patients and controls were white. Table 1 summarizes
the demographic characteristics and prevalence of tradi-
tional cardiovascular risk factors in patients and controls.
The prevalence of hypertension, hypercholesterolemia,
and hypertriglyceridemia was higher among primary SS
patients compared to healthy controls. There was also
higher frequency of primary SS patients taking antihyper-
tensive and statin therapies. Primary SS patients had
lower proportions of current smokers and oral contracep-
tive users than healthy controls. Thirty percent of patients
were taking hydroxychloroquine, 10% were taking ste-
roids, and 6% were taking immunosuppressants, with
none of the controls taking any of these medications. Pa-
tients were younger than controls (mean  SD age 45.8 
11.8 versus 59.1 12.4 years; P 0.001). Since age is a key
determinant of blood pressure and serum lipid levels, we
stratiﬁed the prevalence of hypertension, hypertriglyc-
emia, and hypercholesterolemia according to age and dem-
onstrated that the percentages of primary SS patients with
hypertension or hypertriglyceridemia were higher than
healthy controls in all age categories. The same was true
for hypercholesterolemia, except for the 60–69 years age
group, where the percentage of patients with hypercholes-
terolemia was higher in the control group (Figure 1).
Subset analysis. In order to further investigate whether
the increased prevalence of hypertension and dyslipide-
mia was a consequence of the younger age of the control
group, we examined a group of 200 primary SS patients
and 200 controls that could be matched for age, sex, and
ethnicity. Supplementary Table 1 (available in the online
version of this article at http://onlinelibrary.wiley.com/
doi/10.1002/acr.22227/abstract) compares the characteris-
tics of primary SS patients included in this subset analysis
with the remaining primary SS cohort. As expected, pa-
tients included in the subset analysis were younger. In
addition, this subset of primary SS patients also had a
lower prevalence of hypertension, with smaller propor-
tions of individuals receiving antihypertensive or statin
therapies, but with higher percentages of subjects taking
antimalarials and oral contraceptives.
The mean SD age of patients and controls in the subset
analysis was 51  10 years. A total of 88.4% of patients
were anti-Ro antibody positive and 68.9% were anti-La
antibody positive with a mean  SD disease duration of
11.5  8.5 years from symptom onset.
Primary SS patients had a lower prevalence of smoking
Figure 1. Distribution of hypertension (HT), hypertriglyceride-
mia, and hypercholesterolemia in primary Sjögren’s syndrome
(PSS) patients and healthy controls (HC) by age group.
Table 1. Demographics and prevalence of








Age, mean  SD years 59.1  12.4 45.8  11.8
Smoking, current 22 (4) 33 (8)
WHO hypertension 203 (37.7) 43 (10.4)
NCEP hypertension 308 (57.3) 94 (23)
Hypercholesterolemia 95 (17.7) 60 (14.5)
Hypertriglyceridemia 127 (23.6) 36 (8.7)
Low HDL 70 (13.1) 43 (12.1)
High LDL 71 (13.2) 55 (15.6)
Diabetes mellitus 19 (3.5) 7 (1.7)
Family history of CVD 67 (12.5) 51 (12.7)
CRP, median (IQR)
mg/dl
5.0 (2.7–7.9) 1.15 (0.0–3.0)
BMI 30 kg/m2 110 (20.4) 67 (16.2)
Antihypertensive use 150 (27.8) 41 (10)
Statin use 84 (15.6) 15 (3.6)
Fibrate use 1 (0.2) 0 (0)
* Values are the number (percentage) unless indicated otherwise.
SS  Sjo¨gren’s syndrome; WHO  World Health Organization;
NCEP  National Cholesterol Education Programme; HDL  high-
density lipoprotein; LDL  low-density lipoprotein; CVD  cardio-
vascular disease; CRP  C-reactive protein; IQR  interquartile
range; BMI  body mass index.
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than healthy controls (3.8% versus 10.1%; P  0.026) and
higher median levels of CRP (5 mg/dl versus 1.2 mg/dl;
P  0.0001). There was no difference in the prevalence of
diabetes mellitus, obesity, or family history of CVD. There
was no correlation between steroid use and diabetes mel-
litus prevalence in either group. Analysis of lipid proﬁles
revealed that 21% of patients had hypertriglyceridemia
compared to 9.5% of controls (P 0.002), but there was no
statistically signiﬁcant difference in the prevalence of hy-
percholesterolemia, low HDL, or high LDL levels (Table 2).
Hypertension was more prevalent in primary SS patients
than in controls regardless of the deﬁnition used. Twenty-
eight percent of patients were classiﬁed as having WHO
hypertension compared to 15% of controls (P  0.003),
while 50% of patients were classiﬁed as having NCEP
hypertension versus 25.6% of controls (P  0.0001).
Odds ratios were calculated to determine the likelihood
of experiencing hypertriglyceridemia and hypertension af-
ter adjusting for smoking, BMI, and steroid, antimalarial,
and antihypertensive use where appropriate. Primary SS
patients were 2.260 (95% conﬁdence interval [95% CI]
1.262–4.080, P  0.006) times more likely to have hyper-
triglyceridemia, 2.02 (95% CI 1.19–3.44, P  0.009) times
more likely to have WHO hypertension, and 2.87 (95% CI
1.83–4.52, P  0.0001) times more likely to have NCEP
hypertension than controls.
Characteristics of patients with hypertension and hy-
pertriglyceridemia. We then analyzed the clinical, labo-
ratory, and immunologic characteristics of hypertensive
and nonhypertensive patients to explore whether hyper-
tensive patients could be identiﬁed on the basis of any of
these characteristics. The only statistically signiﬁcant dif-
ference found was antihypertensive use, with 28% of hy-
pertensive patients on treatment compared to 12% of non-
hypertensive patients (P  0.007). The same analysis was
carried out for hypertriglyceridemia and nonhypertriglyc-
eridemia primary SS patients and is shown in Table 3.
Hypertriglyceridemia primary SS patients were more
likely to have abnormal salivary ﬂow test ﬁndings (95.2%
versus 81.3%; P  0.003), to have positive antinuclear
antibodies (ANAs; 90.6% versus 70.6%; P  0.02), and to
be taking antihypertensives (P  0.0001) than their non-
hypertriglyceridemia counterparts. Of note, neither steroid
nor hydroxychloroquine use inﬂuenced the prevalence of
hypertension or hypertriglyceridemia.
Management of hypertension in primary SS patients.
Forty of the 200 primary SS patients from the subset ana-
lysis were known to have hypertension and were taking
antihypertensive treatment. Out of these 40 patients on
treatment, 12 had controlled hypertension, while the re-
maining 28 remained hypertensive despite medication (in-
adequately controlled hypertension). These ﬁndings are
summarized in Table 4.
Therefore, only 28 of the 100 hypertensive primary SS
patients identiﬁed had prior knowledge of their condition,
with 72 primary SS patients being diagnosed as hyperten-
sive during the course of this study. In order to determine
how many of these patients should be taking antihyper-
tensive treatment, we applied the National Institute for
Health and Care Excellence guidance on clinical manage-
ment of hypertension in adults (17). For patients with
hypertension, the need for drug treatment (in addition to
lifestyle modiﬁcations) depends on the absolute blood
pressure value, patient’s age, and comorbidities. However,
if SBP 160 mm Hg or DBP 100 mm Hg (stage 2 hyper-
tension), drug treatment is warranted regardless of comor-
bidities if ambulatory blood pressure monitoring conﬁrms
hypertension (16). Applying this guidance to our cohort,
16 of the 100 hypertensive primary SS patients would be
expected to be on drug treatment. To our surprise, only
44% of these patients were taking antihypertensive agents
(and were therefore experiencing inadequately controlled
Table 2. Prevalence of traditional cardiovascular risk factors in age-matched primary




(n  200) P
Smoking 7 (3.8) 20 (10.1) 0.026
WHO hypertension 56 (28) 31 (15.5) 0.003
NCEP hypertension 100 (50) 51 (25.6)  0.0001
Hypercholesterolemia 38 (19) 35 (17.5) 0.796
Hypertriglyceridemia 42 (21) 19 (9.5) 0.002
Low HDL 33 (16.5) 26 (13) 0.398
High LDL 33 (16.5) 37 (18.5) 0.693
Diabetes mellitus 6 (3) 4 (2) 0.543
Family history of CVD 31 (15.5) 34 (17) 0.398
CRP, median (IQR) mg/dl 5.0 (2.7–7.0) 1.2 (0.0–2.8)  0.0001
BMI 30 kg/m2 39 (19.5) 37 (18.6) 0.899
Antihypertensive use 40 (20) 28 (14) 0.143
Statin use 12 (6) 9 (4.5) 0.655
Fibrate use 0 (0) 0 (0) 1.000
* Values are the number (percentage) unless indicated otherwise. SS  Sjo¨gren’s syndrome; WHO 
World Health Organization; NCEP  National Cholesterol Education Programme; HDL  high-density
lipoprotein; LDL  low-density lipoprotein; CVD  cardiovascular disease; CRP  C-reactive protein;
IQR  interquartile range; BMI  body mass index.
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hypertension), while the other 56% were not receiving
antihypertensive drugs (and were therefore experiencing
untreated hypertension). When the same cutoff was ap-
plied to the healthy controls, we identiﬁed 4 patients
requiring treatment. Of these, 3 patients were taking med-
ication and 1 was not.
Prevalence of cardiovascular events. A total of 7 car-
diovascular events were recorded in the primary SS pa-
tients included in the subset analysis. One patient had an
MI, while another 6 patients experienced strokes. There
were no recorded peripheral vascular disease events. All
7 patients had positive anti-Ro and anti-La antibody test
ﬁndings and experienced hypertension (4 controlled, 3
uncontrolled). None of the patients were smokers, 2 of
them experienced hypertriglyceridemia, and 1 experi-
enced hypercholesterolemia. Information on cardiovas-
cular events was not available for healthy controls and
therefore direct comparisons between groups could not be
drawn.
DISCUSSION
We have determined the prevalence of traditional cardio-
vascular risk factors, using established deﬁnitions, in a
large multicenter cohort of white female primary SS pa-
tients in the UK. We found that primary SS patients were
more than 2 times more likely to experience hypertension
and hypertriglyceridemia than age- and sex-matched
healthy controls. Furthermore, a signiﬁcant proportion of
the hypertensive patients were not previously known to
experience hypertension, and many of those who should
have been on antihypertensive medications were not re-
ceiving them. Hypertension in primary SS is therefore
underdiagnosed and suboptimally treated.
Hypertension is the most important modiﬁable risk fac-
tor for CVD, being more common than cigarette smoking,
dyslipidemia, or diabetes mellitus (18). Hypertension in
primary SS may, at least in part, be explained by the
increased prevalence of subclinical atherosclerosis (11)
seen in these patients. Accelerated atherosclerosis leads to
Table 3. Clinical and laboratory characteristics of hypertriglyceridemia vs. non-





(n  158) P
Abnormal Schirmer’s test 22 (52.4) 83/157 (52.9) 1.000
Abnormal salivary ﬂow test 40 (95.2) 126/155 (81.3) 0.030
Abnormal parotid sialography 4/5 (80.0) 9/18 (50.0) 0.339
Positive salivary gland biopsy 11/17 (64.7) 39/53 (73.6) 0.543
CRP, median (IQR) 3.25 (1.7–5.5) 1.5 (0–4.5) 0.477
Positive anti-Ro 35/41 (85.3) 140/157 (89.1) 0.583
Positive anti-La 28/41 (68.2) 105/157 (66.8) 0.704
Positive ANA 29/32 (90.6) 77/109 (70.6) 0.021
Positive RF 23/32 (71.9) 76/110 (69.1) 0.830
Antihypertensive use 18 (42.9) 22 (13.9)  0.0001
Statin use 2 (4.7) 10 (6.3) 1.000
Steroid use 6 (14.3) 9 (5.6) 0.092
Antimalarial use 14 (33.3) 59 (37.3) 0.720
Fibrate use 0 (0) 0 (0) 1.000
* Values are the number (percentage) or the number/total number (percentage). SS Sjo¨gren’s syndrome;
CRP  C-reactive protein; IQR  interquartile range; ANA  antinuclear antibody; RF  rheumatoid
factor.
Table 4. Blood pressure values and antihypertensive treatment in primary SS patients and







Primary SS patients, no.
Taking antihypertensives 12 28 7
Not taking antihypertensives 88 72 9
Total 100 100 16
Healthy controls, no.
Taking antihypertensives 10 18 3
Not taking antihypertensives 139 33 1
Total 149 51 4
* SS  Sjo¨gren’s syndrome.
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increased cardiovascular events and deaths (19,20) and
has been well documented in other chronic inﬂammatory
conditions such as RA (20) and SLE (21). In primary SS,
immune-mediated arterial wall damage has been postu-
lated as the underlying cause for accelerated atherosclero-
sis (11). In RA, age, BMI, and steroid use have been inde-
pendently associated with hypertension (22). In our study,
there was no difference in BMI between primary SS pa-
tients and controls, and the effects of age and steroid use
were corrected for statistically. Despite this, hypertension
was still more prevalent in primary SS patients than in
controls. This suggests that the effect of other factors (such
as genetic, immunologic, and/or inﬂammatory) may be
more important. Indeed, hypertension has been shown to
be associated with speciﬁc genetic polymorphisms in RA
patients (23,24) and such associations and other potential
mechanisms need to be investigated further in primary SS.
In apparent contrast with our results, Perez de Lis et al (9)
reported a lower prevalence of hypertension in primary SS
patients compared to primary care controls. However, it is
worth noting that 46% of the individuals in their control
group were hypertensive. This led them to hypothesize
that their ﬁnding may be a paradoxical effect due to a
higher prevalence of hypertension in the control group
and recognized it as a limitation of their study. Of note,
they found 30% of hypertensive patients in their primary
SS group, a similar ﬁgure to that found in our cohort. In
contrast to this study, a signiﬁcant proportion of the indi-
viduals in our control group experienced undiagnosed and
sometimes untreated hypertension. While the optimal
management of hypertension was not a primary aim of our
study and while this does not alter our main ﬁnding of a
high prevalence of hypertension in primary SS patients,
these ﬁndings suggest that hypertension may be under-
treated both in primary SS and healthy controls.
Data on the lipid proﬁle of primary SS patients are
scarce. In the US, Lodde et al (12) reported lower HDL and
total cholesterol levels in female primary SS patients (n 
46) than in xerostomic controls (n  12). They analyzed
mean fasting lipid values but did not calculate the preva-
lence of hypercholesterolemia, hypertriglyceridemia, high
LDL, and low HDL using established deﬁnitions (16). The
raw values of serum lipids of primary SS patients between
their study and ours were similar, but different for the
control cohorts. Of note, the lipid proﬁle of their xero-
stomic controls was signiﬁcantly different from that of the
healthy age-matched US population. Our results concur
with those of Perez de Lis et al (9), who, using the same
deﬁnition of hypertriglyceridemia as our study, found a
higher prevalence of hypertriglyceridemia in primary SS
patients than controls (22% versus 15%; P  0.023). The
cause of the abnormal lipid proﬁle in primary SS may be,
as in RA (25), multifactorial and, together with its clinical
signiﬁcance, is yet to be fully explored. Corticosteroid use
can cause dyslipidemia. However, the prevalence of hy-
pertriglyceridemia was not increased in primary SS pa-
tients on steroid treatment compared to those who were
not on treatment (data not shown), and the percentage of
hypertriglyceridemia primary SS patients taking steroids
was not signiﬁcantly higher than that of their nonhyper-
triglyceridemia counterparts (14.3% versus 5.6%; P 
0.092) (Table 3). Interestingly, we have identiﬁed that pa-
tients with hypertriglyceridemia are more likely to have
abnormal salivary ﬂow test ﬁndings and positive ANAs
than nonhypertriglyceridemia patients. While these ﬁnd-
ings need to be validated in different cohorts, this obser-
vation may aid stratiﬁcation of primary SS patients who
may beneﬁt from analysis of lipid proﬁle.
Seven primary SS patients experienced cardiovascular
events. All of them were hypertensive and had positive
anti-Ro and anti-La antibody testing. Information regard-
ing disease duration at the time of cardiovascular events
was not collected. The issue of whether cardiovascular
risk factors translate into increased cardiovascular risk in
primary SS patients is an important one and has not been
studied in detail. Perez de Lis et al described cardiovascu-
lar events in primary SS patients but reported that their
prevalence did not differ from that of the control popula-
tion (9). We were unable to perform such comparison as
we lacked the relevant data for the control group. Never-
theless, in the light of our ﬁndings and that of others, a
longitudinal study of cardiovascular risk and events in
primary SS patients is warranted.
The proportion of current smokers in the primary SS
group was signiﬁcantly lower than that in the control
group (3.8 versus 10.1; P  0.02). The reason for this
observation is unclear, but has also been reported in an-
other study (9) and may be related to the potential link
between smoking and aggravation of xerostomia.
Median CRP levels were higher in primary SS patients
than controls. This is in keeping with ﬁndings from pre-
vious studies (9,12). The association between CVD and
inﬂammation is widely recognized and CRP levels have
been used as reliable markers of inﬂammation. The Amer-
ican Heart Association has deﬁned risk groups for CVD
according to high-sensitivity CRP (hsCRP) values (26),
where an hsCRP level of 1.0 mg/dl, 1.0–2.9 mg/dl, and
3.0 mg/dl confers low, moderate, and high risk, respec-
tively. Although these values are not intended for use in
isolation but in conjunction with other cardiovascular risk
factors, they act as good indicators of cardiovascular risk.
Although CRP levels in our study were measured using
routine laboratory tests, the higher values found in the
primary SS group support the idea that inﬂammation may
act as an additional and independent risk factor for CVD in
primary SS patients.
Perez de Lis et al (9) described a higher prevalence of
diabetes mellitus in primary SS patients than in controls.
Our study did not conﬁrm this ﬁnding. One possible ex-
planation is that the deﬁnitions of diabetes mellitus used
in these 2 studies were different. However, the magnitude
of the difference between studies (3.4% versus 27%) war-
rants further investigation into the underlying reasons.
Glucocorticoid use is a risk factor for diabetes mellitus. In
this study, there was no apparent correlation between
glucocorticoid use and diabetes mellitus as 2 of 53 (3.8%)
primary SS patients taking glucocorticoids and 17 of 485
(3.8%) primary SS patients not on glucocorticoids had
diabetes mellitus (P  1.000).
In addition to traditional cardiovascular risk factors,
there is now growing interest in the role of nontraditional
cardiovascular risk factors. Of particular relevance to pri-
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mary SS is the potential role of oral inﬂammation and
hygiene as risk factors for cardiovascular events (27,28)
since poor oral hygiene and oral mucosal disease are com-
mon among primary SS patients. Future studies investi-
gating the link of oral health in primary SS and cardiovas-
cular risk would be of great interest.
The strengths of this study include prospective and stan-
dardized data collection, a large sample size, and patient
recruitment from multiple centers, which increases the
ecological validity of the ﬁndings. This study, however, is
not without limitations. The control cohort was younger,
but our observations of increased prevalence of hyperten-
sion and hypertriglycaemia in primary SS patients were
conﬁrmed in our subset analysis of age- and sex-matched
groups. Some of the individuals in the control cohort were
hospital employees. This may have introduced a healthy
worker effect bias (29) by which morbidity in this group
may be lower than in the general population. However,
among the hospital employees, there was a diversity of
occupations within this group (nurses [19%], administra-
tive and clerical staff [35%], porters and kitchen workers
[17%], doctors [3%], and others [26%]) reﬂecting a variety
of socioeconomic and educational backgrounds. Further-
more, analysis of lifestyle preferences in the control group
revealed that more than half the participants did not un-
dertake regular exercise and 60% were ex-smokers. These
ﬁgures are similar to the general population, arguing
against a signiﬁcant healthy-worker bias in this group.
A large body of research led to the recognition of in-
creased cardiovascular risk in RA. This in turn has led to
recommendations of yearly cardiovascular checks in RA
patients (7), although adherence to this guideline in daily
practice remains suboptimal (30). A similar approach has
been proposed in order to assess and treat the increased
cardiovascular risk associated with SLE (31). In contrast,
cardiovascular risk is not routinely considered during as-
sessment of primary SS patients. Our ﬁndings warrant
further investigation in this area and will alert clinicians
that an association between increased cardiovascular risk
and primary SS exists.
Primary SS patients have higher prevalence of hyperten-
sion and hypertriglyceridemia than healthy individuals.
Clinicians need to be aware of this increased risk in order
to take appropriate steps to assess cardiovascular risk and
treat it where appropriate.
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APPENDIX A: ADDITIONAL MEMBERS OF THE UK
PRIMARY SJÖGREN’S SYNDROME REGISTRY
In addition to Drs. Bowman, Grifﬁths, and Ng, who are inves-
tigators of the UKPSSR, and Drs. Bowman, Price, Ng, and Kitas,
who are investigators of the UKPSSR cardiovascular substudy, the
other UKPSSR members include, in alphabetical order of their
afﬁliations: Elalaine C. Bacabac, Robert Moots (Aintree University
Hospitals); Michele Bombardieri, Constantino Pitzalis, Nurhan
Sutcliffe (Bart and the London NHS Trust); Nagui Gendi (Basildon
Hospital); John Hamburger, Andrea Richards (Birmingham Dental
Hospital); Saaeha Rauz (Birmingham & Midland Eye Centre); Sue
Brailsford (Birmingham University Hospital); Paul Allcoat, John
McLaren (Whyteman’s Brae Hospital, Fife); Joanne Logan Diar-
muid Mulherin (Cannock Chase Hospital); Jacqueline Andrews,
Paul Emery, Colin Pease, Christine Thomas (Chapel Allerton Hos-
pital, Leeds); Alison Booth, Marian Regan (Derbyshire Royal In-
ﬁrmary); Esther Gordon, Cathy Lawson (Harrogate District Foun-
dation Trust Hospital); Monica Gupta, John Hunter, Lesley Stirton
(Gartnavel General Hospital, Glasgow); Gill Ortiz, Elizabeth Price
(Great Western Hospital); Gavin Clunie, Ginny Rose (Ipswich
Hospital NHS Trust); Susan Knight, Deborah Symmons, Beverley
Jones (Macclesﬁeld District General Hospital & Arthritis Research
UK Epidemiology Unit, Manchester); Suzanne Edgar, Marco Car-
rozzo, Francisco Figuereido, Heather Foggo, Iain Macleod, Dennis
Lendrem, Sheryl Mitchell (Newcastle upon Tyne Hospitals NHS
Foundation Trust); Adrian Jones, Peter Lanyon, Alice Muir (Not-
tingham University Hospital); Paula White, Steve Young-Min
(Portsmouth Hospitals NHS Trust); Susan Pugmire, Saravanan
Vadivelu (Queen’s Elizabeth Hospital, Gateshead); Annie Cooper
(Royal Hampshire County Hospital); Anne Field, Stephen Kaye,
Devesh Mewar (Royal Liverpool University Hospital); Neil
McHugh, John Pauling, Julie James (Royal National Hospital for
Rheumatic Diseases); Mohammed Akil, Jayne McDermott (Royal
Shefﬁeld Hospital); David Coady, Elizabeth Kidd (Royal Sunder-
land Hospital); Bhaskar Dasgupta, Pamela Long (Southend Uni-
versity Hospital); and Ada Ferenkeh-Koroma, Stefano Fedele, Ian
Giles, David Isenberg, Stephen Porter (University College Hospital
& Eastman Dental Institute).
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